Clinical Trials Logo

Filter by:
NCT ID: NCT05437380 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC

Start date: September 20, 2022
Phase: N/A
Study type: Interventional

Head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Cervical lymph node metastasis is frequently encounted on the date of diagnosis. Surgical resection is one of the most important treatment methods for head and neck squamous cell carcinoma with or without lymph node metastasis. At present, for cN0 patients, prophylactic neck dissection is recommended for squamous cell carcinoma originating in suprglottic, hypopharyngeal and oropharyngeal areas et al. Related studies reported that less than 30% of patients with cN0 were confirmed to have lymph node metastasis in postoperative pathological examination, who underwent neck dissection. Unnecessary neck dissection may increase complication incidence, such as neurovascular injury, chylous leakage, sialosyrinx. Accurate preoperative assessment is helpful to reduce unnecessary neck dissection. Sentinel lymph node biopsy were proved to be effective in reducing prophylactic lymph node dissection in breast cancer, melanoma and other malignant tumors. Compared with γ probe detection and indolyanine green injection, microbubble and contrast-enhanced ultrasound has no radiation and disturbance to resection margins in sentinel lymph nodes detection. Furthermore, surgeons could conduct lymph node puncture biopsy simultaneously under ultrasound guidance, which can further minimize surgical trauma. At present, the role of microbubble and contrast-enhanced ultrasound in sentinel lymph node detection and biopsy is rarely reported in head and neck squamous cell carcinoma. This study aims to explore the accuracy of peritumoral microbubbles and contrast-enhanced ultrasound for sentinel lymph nodes biopsy in predicting cervical lymph node metastasis in head and neck squamous cell carcinoma.

NCT ID: NCT05437341 Recruiting - Cancer Disease Clinical Trials

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the feasibility, safety and efficacy of anti-PSMA/CD70 bi-specific CAR-T cell therapy in patients with CD70 and PSMA positive malignancies. Another goal of the study is to learn more about the function of the PSMA/CD70 bi-specific CAR-T cells and their persistency in patients.

NCT ID: NCT05437328 Recruiting - Malignant Disease Clinical Trials

GD2/CD56 Bi-specific CAR-T Cell Therapy

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another goal of the study is to learn more about the function of the anti-GD2/CD56 bi-specific CAR-T cells and their persistency in patients.

NCT ID: NCT05437315 Recruiting - Solid Tumor Clinical Trials

GD2/PSMA Bi-specific CAR-T Cell Therapy

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/PSMA bi-specific CAR-T cell therapy in patients with GD2 and PSMA positive tumor. Another goal of the study is to learn more about the function of the anti-GD2/PSMA bi-specific CAR-T cells and their persistency in patients.

NCT ID: NCT05436964 Recruiting - Delirium in Old Age Clinical Trials

Effect of Intraoperative Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing Major Abdominal Surgery

Start date: June 27, 2022
Phase: N/A
Study type: Interventional

To observe the effect of intraoperative dexmedetomidine on the incidence of postoperative delirium, postoperative analgesic drug requirements and pain scores in elderly patients undergoing major abdominal surgery.

NCT ID: NCT05436561 Recruiting - Clinical trials for Disease-free Survival

Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML >=55 years.

NCT ID: NCT05436522 Recruiting - Clinical trials for Intraoperative Hypotension

REmimazolam vs PrOpofol on Intraoperative hypotenSion in Major Noncardiac surgEry

REPOSE-1
Start date: August 22, 2022
Phase: Phase 4
Study type: Interventional

Intraoperative hypotension is common during major noncardiac surgery and is associated with adverse postoperative outcomes. Propofol, the most commonly used intravenous anesthetic agent worldwide, is associated with hypotension on induction and maintenance of general anesthesia. Remimazolam is a newly developed short-acting benzodiazepine drug and has been approved for use in procedural sedation and general anesthesia. It was associated with a lower incidence of hypotension during procedural sedation in previous studies. The aim of this study is to tested the primary hypothesis that total intravenous anesthesia with remimazolam reduces the duration and severity of hypotension during major noncardiac surgery compared with total intravenous anesthesia with propofol.

NCT ID: NCT05436509 Recruiting - B Cell Malignancies Clinical Trials

CD19/79b Bi-specific CAR-T Cell Therapy

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/79b bi-specific CAR-T cells and their persistency in patients.

NCT ID: NCT05436496 Recruiting - B Cell Malignancies Clinical Trials

CD19/70 Bi-specific CAR-T Cell Therapy

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the feasibility, safety and efficacy of CD19/70 bi-specific CAR-T cell therapy in patients with CD19 and/or CD70 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/70 bi-specific CAR-T cells and their persistency in patients.

NCT ID: NCT05436223 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Start date: August 9, 2021
Phase: Phase 2
Study type: Interventional

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.